Business Context and Reporting Period
This Form 8-K, dated November 5, 2025, reports on Atai Beckley N.V. (formerly ATAI Life Sciences N.V.), a company incorporated in The Netherlands and listed on the Nasdaq Global Market under the symbol ATAI. The filing documents the completion of a strategic acquisition and a subsequent corporate name change.
Key Financial Metrics and Transaction Details
The filing focuses on a specific corporate transaction rather than periodic financial performance metrics such as revenue, profit, or cash flow.
- Transaction Type: Acquisition of 100% of the issued share capital of Beckley Psytech Limited (Beckley Psytech).
- Consideration: The Company issued an aggregate of 103,000,066 ordinary shares to Beckley Psytech shareholders, consultants, and equity award holders.
- Financial Statements: This 8-K does not contain audited financial statements, liquidity data, debt levels, or margin analysis for the reporting period.
Material Changes
The following material changes were effected on November 5, 2025:
- Acquisition Completion: Finalized the purchase of Beckley Psytech pursuant to the Share Purchase Agreement dated June 2, 2025.
- Corporate Name Change: The registrant officially changed its name from "ATAI Life Sciences N.V." to "Atai Beckley N.V.".
- Capital Structure: Significant dilution occurred via the issuance of over 103 million new ordinary shares as consideration for the acquisition.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the successful completion of the strategic combination, positioning the new entity as a "Global Leader in Transformative Mental Health Therapies."
- Guidance: No specific financial guidance or forward-looking revenue projections are provided in this filing.
- Risks and Contingencies: The filing references the Share Purchase Agreement (Exhibit 2.1) for a complete description of terms but does not explicitly detail new risks or contingencies within the text of the 8-K itself.
- Unusual Items: The issuance of a large block of shares (103,000,066) constitutes a significant capital event.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Review the full Share Purchase Agreement (Exhibit 2.1) for earn-out provisions, indemnities, or contingent consideration not detailed in the summary.
- Confirm the integration timeline and operational synergies outlined in the press release (Exhibit 99.1).
- Check subsequent filings for the updated capitalization table and any changes to the board of directors resulting from the acquisition.